BR112022009864A2 - Variantes do vetor viral adenoassociado - Google Patents
Variantes do vetor viral adenoassociadoInfo
- Publication number
- BR112022009864A2 BR112022009864A2 BR112022009864A BR112022009864A BR112022009864A2 BR 112022009864 A2 BR112022009864 A2 BR 112022009864A2 BR 112022009864 A BR112022009864 A BR 112022009864A BR 112022009864 A BR112022009864 A BR 112022009864A BR 112022009864 A2 BR112022009864 A2 BR 112022009864A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral vector
- variants
- associated viral
- targeting peptides
- modified capsid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
VARIANTES DO VETOR VIRAL ADENOASSOCIADO. A presente invenção refere-se a peptídeos de direcionamento e vetores contendo uma sequência que codifica os peptídeos de direcionamento que liberam agentes às subestruturas específicas no cérebro. Fornecidos neste documento são os vetores virais contendo cada qual um capsídeo modificado, em que o capsídeo modificado compreende pelo menos uma sequência de aminoácido que direciona o vetor viral a uma estrutura cerebral distinta.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962939315P | 2019-11-22 | 2019-11-22 | |
US202063084709P | 2020-09-29 | 2020-09-29 | |
PCT/US2020/061464 WO2021102234A1 (en) | 2019-11-22 | 2020-11-20 | Adeno-associated viral vector variants |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022009864A2 true BR112022009864A2 (pt) | 2022-08-02 |
Family
ID=75980202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022009864A BR112022009864A2 (pt) | 2019-11-22 | 2020-11-20 | Variantes do vetor viral adenoassociado |
Country Status (12)
Country | Link |
---|---|
US (2) | US20230346981A1 (pt) |
EP (1) | EP4061427A4 (pt) |
JP (1) | JP2023503455A (pt) |
KR (1) | KR20220116459A (pt) |
CN (1) | CN115023242A (pt) |
AU (1) | AU2020388404A1 (pt) |
BR (1) | BR112022009864A2 (pt) |
CA (1) | CA3159113A1 (pt) |
CO (1) | CO2022008507A2 (pt) |
IL (1) | IL293140A (pt) |
MX (1) | MX2022006188A (pt) |
WO (1) | WO2021102234A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023205397A1 (en) * | 2022-04-22 | 2023-10-26 | The Children's Hospital Of Philadelphia | Human ependyma-specific promoter and uses thereof |
WO2023220287A1 (en) * | 2022-05-11 | 2023-11-16 | The Children's Hospital Of Philadelphia | Adeno-associated viral vectors for targeting deep brain structures |
WO2023220386A1 (en) * | 2022-05-13 | 2023-11-16 | The Children's Hospital Of Philadelphia | Adeno-associated viral vectors for targeting brain microvasculature |
WO2023225481A1 (en) | 2022-05-16 | 2023-11-23 | Genzyme Corporation | Methods of treating metachromatic leukodystrophy |
WO2024017387A1 (en) * | 2022-07-22 | 2024-01-25 | Shanghai Vitalgen Biopharma Co., Ltd. | Novel aav capsids for targeting nervous system and uses thereof |
KR20240029316A (ko) * | 2022-08-26 | 2024-03-05 | 경희대학교 산학협력단 | 활막 표적화 화합물 및 이의 용도 |
WO2024064673A2 (en) * | 2022-09-19 | 2024-03-28 | The Children's Hospital Of Philadelphia | Aav evolution at single-cell resolution using split-seq |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
FI3517134T3 (fi) * | 2001-12-17 | 2024-04-03 | Univ Pennsylvania | Adeno-assosioituneen viruksen (aav) serotyypin 8 sekvenssejä, niitä sisältäviä vektoreita ja niiden käyttöjä |
AU2018221738A1 (en) * | 2017-02-15 | 2019-08-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for gene transfer across the vasculature |
BR112019023869A2 (pt) * | 2017-05-12 | 2020-06-09 | Childrens Hospital Philadelphia | variantes de sulfamidase (sgsh), vetores, composições e métodos e usos para tratar mucopolissacaridose tipo iiia (mps iiia) |
JP6825167B2 (ja) * | 2017-09-20 | 2021-02-03 | 4ディー モレキュラー セラピューティクス インコーポレイテッド | アデノ随伴ウイルス変異キャプシドおよびその使用方法 |
EP3687582A4 (en) * | 2017-09-29 | 2021-07-14 | Voyager Therapeutics, Inc. | RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION |
WO2019113538A2 (en) * | 2017-12-07 | 2019-06-13 | California Institute Of Technology | Methods and systems for noninvasive control of brain cells and related vectors and compositions |
TW202015742A (zh) * | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒(aav)之組成物和方法 |
-
2020
- 2020-11-20 US US17/778,783 patent/US20230346981A1/en active Pending
- 2020-11-20 IL IL293140A patent/IL293140A/en unknown
- 2020-11-20 CN CN202080094086.2A patent/CN115023242A/zh active Pending
- 2020-11-20 BR BR112022009864A patent/BR112022009864A2/pt unknown
- 2020-11-20 EP EP20890214.8A patent/EP4061427A4/en active Pending
- 2020-11-20 CA CA3159113A patent/CA3159113A1/en active Pending
- 2020-11-20 JP JP2022529681A patent/JP2023503455A/ja active Pending
- 2020-11-20 KR KR1020227021143A patent/KR20220116459A/ko unknown
- 2020-11-20 MX MX2022006188A patent/MX2022006188A/es unknown
- 2020-11-20 WO PCT/US2020/061464 patent/WO2021102234A1/en active Application Filing
- 2020-11-20 AU AU2020388404A patent/AU2020388404A1/en active Pending
-
2022
- 2022-06-16 CO CONC2022/0008507A patent/CO2022008507A2/es unknown
-
2023
- 2023-10-20 US US18/491,365 patent/US20240100194A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022006188A (es) | 2022-08-22 |
AU2020388404A1 (en) | 2022-06-09 |
EP4061427A4 (en) | 2024-01-10 |
CO2022008507A2 (es) | 2022-07-08 |
CA3159113A1 (en) | 2021-05-27 |
JP2023503455A (ja) | 2023-01-30 |
KR20220116459A (ko) | 2022-08-23 |
US20230346981A1 (en) | 2023-11-02 |
CN115023242A (zh) | 2022-09-06 |
EP4061427A1 (en) | 2022-09-28 |
WO2021102234A1 (en) | 2021-05-27 |
IL293140A (en) | 2022-07-01 |
US20240100194A1 (en) | 2024-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022009864A2 (pt) | Variantes do vetor viral adenoassociado | |
CL2018002825A1 (es) | Vacuna contra vrs | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
BR112018003665A2 (pt) | métodos e composições para vetores virais de evasão de anticorpo | |
BR112017017867A2 (pt) | métodos e composições para tratamento de doenças oculares genéticas | |
BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
CY1120485T1 (el) | Μεθοδοι για τη συζευξη πεπτιδιων-στοχων με ανασυνδυασμενα λυσοσωμικα ενζυμα για βελτιωμενες θεραπευτικες αγωγες διαταραχων λυσοσωμικης αποθηκευσης | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
BR112018009645A2 (pt) | composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias | |
EA201891137A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
MX2018006840A (es) | Focalizacion de peptidos para dirigir virus adenoasociados. | |
BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
EA201890640A1 (ru) | Рекомбинантные векторы, содержащие пептид 2а | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
EA201892006A1 (ru) | Aav-опосредованная экспрессия с использованием синтетического промотора и энхансера | |
PE20181049A1 (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia | |
BR112016025263A2 (pt) | vetores de avv para terapia genética retiniana e do snc | |
AR118928A1 (es) | Métodos de redosificación de vectores de terapia génica | |
BR112018071167A2 (pt) | entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular | |
EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
BR112018075692A2 (pt) | genes cln1 otimizados e cassetes de expressão e seu uso | |
EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand |